Compare PLNT & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLNT | ARWR |
|---|---|---|
| Founded | 1992 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 9.4B |
| IPO Year | 2015 | 1993 |
| Metric | PLNT | ARWR |
|---|---|---|
| Price | $91.68 | $65.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 11 |
| Target Price | ★ $121.82 | $77.55 |
| AVG Volume (30 Days) | 1.8M | ★ 2.6M |
| Earning Date | 02-24-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.23 | N/A |
| EPS | ★ 2.44 | N/A |
| Revenue | ★ $1,202,700,000.00 | $829,448,000.00 |
| Revenue This Year | $21.43 | N/A |
| Revenue Next Year | $11.05 | N/A |
| P/E Ratio | $37.97 | ★ N/A |
| Revenue Growth | 14.63 | ★ 23258.15 |
| 52 Week Low | $87.72 | $9.57 |
| 52 Week High | $114.47 | $76.76 |
| Indicator | PLNT | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 24.55 | 51.68 |
| Support Level | $96.18 | $65.65 |
| Resistance Level | $99.01 | $68.80 |
| Average True Range (ATR) | 3.33 | 3.01 |
| MACD | -0.94 | -0.41 |
| Stochastic Oscillator | 1.93 | 46.92 |
Planet Fitness Inc is a franchisor and operator of fitness centers in the United States. The company's reportable segments are Franchise, Corporate-owned stores, and Equipment. Franchise segment includes operations related to its franchising business in the United States, Puerto Rico, Canada, Panama, Mexico and Australia, Corporate-owned stores segment includes operations with respect to all corporate-owned stores throughout the United States and Canada, and The Equipment segment includes the sale of equipment to franchisee-owned stores in the U.S. The firm generates a majority of its revenue from the Corporate-owned stores segment.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.